GTX-102 in Children With Angelman Syndrome (KIK-AS)

This is a Phase 1/2, open-label, multiple-dose, dose-escalating study to evaluate the safety, tolerability, and plasma and cerebrospinal fluid (CSF) concentrations of GTX-102 in pediatric patients with Angelman syndrome. Approximately 20 patients (male and female) ≥ 4 and ≤ 17 years of age with a genetically confirmed diagnosis of full maternal UBE3A gene deletion (within 15q11.2-q13 region) will be enrolled.

The study includes screening, baseline, treatment, and safety follow-up periods. Eligible patients who meet all of the inclusion criteria and none of the exclusion criteria and who successfully complete all screening and baseline assessments will be assigned to one of 5 sequential dose cohorts. GTX-102 will be administered by intrathecal (IT) injection via lumbar puncture (LP) at Baseline followed by 3 subsequent IT injections on study Days 30, 58 and 86. The procedure for IT administration of GTX-102 will performed by a clinician with experience in LP and anesthetic care will be directed by experienced anesthesiologists with a focus on patient safety and comfort. The total duration of study for each patient is anticipated to be approximately 6 months. An open-label extension (OLE) study will be conducted under a separate protocol where patients can receive continued treatment with GTX-102.